Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7479177 | 0.82 | MAOA (0.57) | MAOAMAOBHTR7CA1CA2 | |
| SCHEMBL3267392 | 0.79 | RAB9A (0.40) | MAOAMAOBHTR7LMNAALDH1A1 | |
| SCHEMBL5333367 | 0.79 | MAOA (0.72) | MAOAMAOBHTR7CA1CA2 | |
| SCHEMBL4602883 | 0.78 | BACE1 (0.44) | MAOAMAOBLMNAALDH1A1CYP2C19 | |
| SCHEMBL10509506 | 0.78 | MTNR1A (0.46) | MAOAMAOBCA1CA2CA4 | |
| SCHEMBL31358088 | 0.76 | MAOA (0.36) | MAOAMAOB | |
| SCHEMBL3598536 | 0.76 | MAOA (0.36) | MAOAMAOB | |
| SCHEMBL30128237 | 0.76 | MAOA (0.36) | MAOAMAOB | |
| SCHEMBL15390878 | 0.76 | MAOA (0.36) | MAOAMAOBALDH1A1CYP2C19CYP2C9 | |
| SCHEMBL3595820 | 0.76 | HPGD (0.36) | MAOAMAOBCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013173382-A1 | BENZOTHIOPHENE SULFONAMIDES AND OTHER COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| EP-1633699-B1 | ARYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| US-7157491-B2 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157491-B2 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157491-B2 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1633699-A2 | ARYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | Wyeth (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050009907-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH | 2005-01-13 | — | — | US | disclosed |
| WO-2004103941-A2 | ARYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009907-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | ESR1, ESR2, ESRRA | MAOA 1245/4885MAOB 1064/4885HTR7 632/4885 |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | ESR1, ESR2, GPER1 | MAOA 1176/4885MAOB 1085/4885HTR7 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.